Significance of Steroid Receptor Immunoassay in Breast Cancer

1989 ◽  
pp. 149-159
Author(s):  
Edward J. Keenan ◽  
Debra Corbin
Keyword(s):  
Breast Cancer ◽  
Steroid Receptor

Relation between steroid receptor status and body weight in breast cancer patients

1992 ◽  
Vol 28 (1) ◽  
pp. 112-115 ◽  
Author(s):  
Dario Giuffrida ◽  
Lorenzo Lupo ◽  
Gianfranco A. La Porta ◽  
Giacomo L. La Rosa ◽  
Giuseppa Padova ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Weight ◽  
Cancer Patients ◽  
Steroid Receptor ◽  
Breast Cancer Patients ◽  
Receptor Status

Immunohistochemical Steroid Receptor Detection in Frozen Breast Cancer Tissue: A multicenter investigation

1988 ◽  
Vol 27 (6) ◽  
pp. 757-760 ◽  
Author(s):  
B. Bruun Rasmussen ◽  
S. M. Thorpe ◽  
T. Nørgaard ◽  
J. Rasmussen ◽  
N. Agdal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Steroid Receptor ◽  
Breast Cancer Tissue ◽  
Cancer Tissue

scholarly journals Steroid Receptor Levels in Breast Cancer: Relationships with Age and menopausal status

1989 ◽  
Vol 28 (6) ◽  
pp. 807-810 ◽  
Author(s):  
N. Wilking ◽  
L. E. Rutqvist ◽  
B. Nordenskjöld ◽  
L. Skoog
Keyword(s):  
Breast Cancer ◽  
Menopausal Status ◽  
Steroid Receptor

Steroid receptor status and the epidemiology of breast cancer

1991 ◽  
Vol 1 (6) ◽  
pp. 513-523 ◽  
Author(s):  
Nancy Kreiger ◽  
Will D. King ◽  
Lynn Rosenberg ◽  
E.Aileen Clarke ◽  
Julie R. Palmer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Steroid Receptor ◽  
Receptor Status

scholarly journals Tamoxifen-induced ER-α–SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence

2006 ◽  
Vol 13 (4) ◽  
pp. 1135-1145 ◽  
Author(s):  
Marie Mc Ilroy ◽  
Fergal J Fleming ◽  
Yvonne Buggy ◽  
Arnold D K Hill ◽  
Leonie S Young
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Cell Cultures ◽  
Human Breast Cancer ◽  
Molecular Model ◽  
Steroid Receptor ◽  
Model Systems ◽  
Endocrine Treatment ◽  
Human Breast ◽  
Her2 Positive

Differential signalling between the two oestrogen receptor (ER) isoforms in the presence of tamoxifen has been described. We hypothesise that differential recruitment of the steroid receptor co-activator, SRC-3 to ER-α and ER-β may in part explain associations between ER isoforms and response to endocrine treatment. SRC-3 was localised within epithelial cells of breast tumour tissue and was co-localised with ER-α and ER-β, (n = 112). Expression of SRC-3 was found to be positively associated with ER-α (P = 0.0021) and inversely with ER-β (P < 0.0001). Uniquely, this study utilises primary cell cultures derived from patient tumours, thus providing samples not readily available in most molecular model systems. These samples have enabled us to investigate the influence of growth factor pathways on steroid receptor-co-activator interactions. In HER2 (human epidermal growth factor receptor 2) positive primary tumour cell cultures 17β-estradiol induced a decrease in SRC-3, whereas upregulated SRC-3 expression. Furthermore, treatment with tamoxifen-induced SRC-3 recruitment to the ER-oestrogen response element and enhanced interaction between SRC-3 and ER-α, but not ER-β. Knockdown of SRC-3 results in a concomitant loss of expression of the oestrogen target gene pS2. Furthermore, silencing of SRC-3 resensitizes endocrine resistant, HER2 positive cells to the anti-proliferative effects of tamoxifen. The ability of ER-α, but not ER-β to recruit SRC-3 in the presence of tamoxifen may in part explain the differential ER isoform associations with recurrence in human breast cancer.

Sign in / Sign up

Export Citation Format

Share Document